ICAD (ICAD) Osake Kurssi

ICAD Inc is primarily active in the healthcare and technology industries.

The main competitors of ICAD Inc in the market include companies like Varian Medical Systems, Elekta AB, and Accuray Incorporated.

ICAD Inc is a renowned company that specializes in advanced image analysis and cancer detection technologies. With a rich history spanning several decades, ICAD Inc was founded in 1984 as a research and development firm focusing on computer-aided detection (CAD) tools for mammography. Over the years, the company expanded its portfolio, offering innovative solutions for various cancer types, including lung, colon, and prostate. With a commitment to improving patient outcomes, ICAD Inc remains at the forefront of cutting-edge medical advancements. Leveraging its expertise in artificial intelligence and machine learning, ICAD Inc continues to deliver state-of-the-art solutions for early cancer detection, contributing to the advancement of medical diagnostics.

ICAD Inc has achieved several significant milestones over the years. Some of these include the development of innovative and leading-edge solutions for advanced imaging in the healthcare industry. The company has also successfully launched its renowned ProFound AI platform, which provides invaluable assistance to radiologists in the early detection of breast cancer. Furthermore, ICAD Inc has consistently focused on expanding its global presence by forging strategic partnerships and collaborations with industry leaders. With a commitment to continuous research and development, ICAD Inc continues to revolutionize the field of medical imaging, ensuring improved patient outcomes and enhanced clinical workflows.

ICAD Inc is primarily present in the United States, with headquarters located in Nashua, New Hampshire. As a leading provider of advanced image analysis technology solutions for the healthcare industry, ICAD Inc serves customers across the United States and also has a strong presence in Europe, Asia, and other regions around the globe. With its innovative solutions and commitment to improving patient outcomes, ICAD Inc continues to expand its reach in healthcare markets worldwide.

ICAD Inc represents values of innovation, collaboration, and dedication to advanced medical imaging technology. With a strong corporate philosophy focused on enhancing patient care and improving clinical outcomes, ICAD Inc continually develops cutting-edge solutions for early cancer detection and radiation therapy. By combining their expertise in artificial intelligence and image analysis, ICAD Inc enables healthcare professionals to make more accurate diagnoses and tailor personalized treatment plans. With a commitment to continuous improvement and providing superior healthcare solutions, ICAD Inc has established itself as a trusted leader in the industry.

Analyytikot asettavat tällä hetkellä ICAD-osakkeelle keskimääräisen tavoitehinnan 3,57 USD (mediaani: 3,57 USD), mikä merkitsee −7,8 % viimeisimpään hintaan verrattuna. Konsensus perustuu 10 analyytikkoarvioon.

ICAD Analyytikkojen kursstavoitteet 2026

10 analyytikkoa arvioi tällä hetkellä ICAD-osaketta: 6 suosittaa ostoa, 4 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat ICAD-yhtiöltä 22,33 M USD liikevaihtoa ja −0,12 USD osakekohtaista tulosta.

ICAD Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla ICAD-osake noteerataan hintaan 3,40 EUR (3,87 USD).

ICAD-osake (ICAD) on listattuna 1 pörssissä, muun muassa: NASDAQ (ICAD).

ICAD Inc is a US-based company that has been operating in the field of medical imaging since 1984. The company's business model focuses on the development and manufacturing of advanced imaging products. ICAD offers two main product lines: iCADx and ProFound AI. iCADx is a specialized group of diagnostic products used in image analysis in radiology and brachytherapy. ProFound AI is a groundbreaking software platform specifically designed for the interpretation of digital breast tomosynthesis (DBT). The two product lines from ICAD allow doctors to obtain more accurate and faster diagnostic results. The iCADx brand offers a range of products for the treatment of breast, prostate, lung, bone, and other types of cancer. The range also includes equipment for brachytherapy, a form of radiation therapy where a radiation source is directly inserted into the body. ProFound AI is an artificial intelligence (AI)-based software platform specifically designed for breast imaging. The system uses state-of-the-art algorithms and image analysis functions to assist the doctor in the early detection and diagnosis of breast cancer. In addition, ICAD also offers professional services such as training, customer support, and technical support. These services are aimed at ensuring that the products are used optimally and achieve the highest quality of imaging and diagnosis. ICAD also operates in the research and development field. The company continuously invests in research and development to improve and further develop its products, in order to provide medical users with the best possible diagnostics. The company also actively collaborates with leading medical institutions, research organizations, and other companies to drive collaborative projects and innovation in the field of medical imaging. In conclusion, it can be said that ICAD's business model is based on state-of-the-art medical imaging technology that improves diagnosis in medical practice. ICAD aims to drive further growth and expansion of the company by constantly improving its technologies and introducing innovative products to the market.

odotettu liikevaihto ICAD on 22,33 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto ICAD on −3,03 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

ICAD:n hinta-voitto-suhde (P/E) on tällä hetkellä −33,65. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan ICAD-osakkeen arvostusta.

ICAD:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,57. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii ICAD-osakkeen arvostuskennuslukuna.

ICAD:n Eulpool-laatuscore on 1/10.

ICAD:n ISIN on US44934S2068. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

ICAD:n WKN on A1J20J. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

ICAD:n ticker on ICAD. Tämä pörssinoteeraus käytetään ICAD-osakkeiden kauppaan pörssissä.

ICAD maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

ICAD kuuluu sektoriin 'Terveydenhuolto'.

ICAD:n osingot jaetaan valuutassa USD.